Journal: Archives of Medical Science : AMS

Article Title: The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway

doi: 10.5114/aoms/152000

Figure Lengend Snippet: Sequences of the immunogenic peptides used in the present study. A 2-lysine-spacer sequence (kk) as the target sequence of cathepsin protease involved in antigen processing

Article Snippet: The vaccine structure includes a short PCSK9 peptide as a B cell epitope inspired by the AFFiRiS group [ , ] linked to a tetanus peptide as a T cell epitope, a pharmaceutically acceptable carrier [ ] ( ).

Techniques: Sequencing, Immunopeptidomics

Journal: Vaccines

Article Title: Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates

doi: 10.3390/vaccines9070749

Figure Lengend Snippet: Sequence of the immunogenic peptides used in the present study.

Article Snippet: To determine the immunogenicity of the L-IFPTA vaccine, titers of antiPCSK9-specific IgG were measured by ELISA technique, using PCSK9 peptide (ChinaPeptides Co., Ltd., Shanghai, China) as the antigen [ ].

Techniques: Sequencing, Immunopeptidomics

Journal: Vaccines

Article Title: Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates

doi: 10.3390/vaccines9070749

Figure Lengend Snippet: ( A ) Antibody titer (ODmax/2) against PCSK9 in vaccinated monkeys at pre-vaccination (W0) and post-vaccination (W8) time-points. ( B ) The exponential increase in antiPCSK9 antibody titer (ODmax/2) over 8 weeks post prime vaccination, generated upon 4 vaccinations in a biweekly interval (signed by arrows). Values are means ± SD ( n = 5).

Article Snippet: To determine the immunogenicity of the L-IFPTA vaccine, titers of antiPCSK9-specific IgG were measured by ELISA technique, using PCSK9 peptide (ChinaPeptides Co., Ltd., Shanghai, China) as the antigen [ ].

Techniques: Generated

Journal: Vaccines

Article Title: Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates

doi: 10.3390/vaccines9070749

Figure Lengend Snippet: In vitro PCSK9/LDLR binding assay. Vaccine-produced antiPCSK9 antibodies suppress the interaction of PCSK9 and LDLR. A plasma sample of monkeys at post-vaccination time-point (W8) could reduce PCSK9 binding to LDLR by −33 ± 7%, when compared with a plasma sample of pre-vaccination ones (W0). Values are means ± SD; n = 3 replicates of the pooled samples of 5 monkeys. The significance compared to pre-vaccination values was analyzed by an unpaired two-tailed Student’s t -test. Statistical differences at p -values less than 0.05 were considered to be significant.

Article Snippet: To determine the immunogenicity of the L-IFPTA vaccine, titers of antiPCSK9-specific IgG were measured by ELISA technique, using PCSK9 peptide (ChinaPeptides Co., Ltd., Shanghai, China) as the antigen [ ].

Techniques: In Vitro, Binding Assay, Produced, Clinical Proteomics, Two Tailed Test